Showing results (1041-1050 of 1,133) with videos related to
Sort By:
Pageof 114
Cancers|November 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment RegistryDaan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, et al.Journal of Cardiac Failure|September 2, 2019
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate UtilizationSharmila Dorbala, Yukio Ando, Sabahat Bokhari, et al.Journal for Immunotherapy of Cancer|August 6, 2020
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-upJoost H van den Berg, Bianca Heemskerk, Nienke van Rooij, et al.The British Journal of Surgery|June 6, 2025
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trialLiselotte Tas, Marie B Weitemeyer, Maartje W Rohaan, et al.BJS Open|May 7, 2020
Preoperative imaging for colorectal liver metastases: a nationwide population-based studyA K E Elfrink, M Pool, L R van der Werf, et al.Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment RegistryJesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2020
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based StudyMichiel C T van Zeijl, John B A G Haanen, Michel W J M Wouters, et al.JCO Oncology Practice|August 9, 2022
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort StudyJesper van Breeschoten, Rawa K Ismail, Michel W J M Wouters, et al.Pageof 114